<DOC>
	<DOCNO>NCT00456898</DOCNO>
	<brief_summary>To evaluate effect multiple oral dos desvenlafaxine sustain release ( DVS SR ) paroxetine biotransformation codeine morphine healthy subject . To assess safety tolerability DVS SR paroxetine coadministered codeine healthy subject .</brief_summary>
	<brief_title>Study Evaluating Potential DVS SR Inhibit CYP2D6 Pathway</brief_title>
	<detailed_description>This randomize , open-label , inpatient/outpatient , 3-period crossover study healthy subjects.The study consist 3 treatment period . In treatment period 1 , subject randomly assign study day 1 . A single 60-mg dose codeine administer subject . In period 2 3 , subject receive either DVS SR 100 mg/day paroxetine 20 mg/day steady state reach . At steady state , subject receive codeine 60 mg concomitantly either DVS SR 100 mg paroxetine 20 mg , depend treatment sequence assign . DVS SR 100 mg paroxetine 20 mg administration continue additional 2 day . In treatment period 3 , subject receive alternative treatment sequence .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<mesh_term>Codeine</mesh_term>
	<criteria>Inclusion criterion : Healthy men nonlactating nonpregnant woman nonchildbearing potential age 18 45 year . Body mass index range 18 30 kg/m2 body weight â‰¥50 kg . Nonsmoker smoker few 10 cigarette per day determine history . Exclusion criterion : History bronchial asthma , seizure disorder ( single childhood febrile seizure ) clinically important drug allergy know allergy desvenlafaxine , venlafaxine , paroxetine , codeine , nonactive excipients dosage form . Use CYP2D6 inhibitor inducer within 30 day test article administration . Demonstration positive orthostatic test screening .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>